defibrotide has been researched along with Kidney-Neoplasms* in 3 studies
1 review(s) available for defibrotide and Kidney-Neoplasms
Article | Year |
---|---|
Treatment of Sinusoidal Obstruction Syndrome With Defibrotide in Pediatric Cancer Patients Following Nontransplant-associated Chemotherapy: A Case Report and Review of the Literature.
Sinusoidal obstruction syndrome (SOS), formerly veno-occlusive disease (VOD), in pediatric cancer patients often presents as a complication of hematopoietic stem cell transplantation, and less commonly secondary to nontransplant-associated chemotherapy. Therapy with defibrotide is well-described as standard care for transplant-associated SOS/VOD, but the treatment of nontransplant-associated SOS/VOD is less clear. We report a 3-year-old with relapsed Wilms tumor and recurrent SOS/VOD, with successful use of defibrotide during chemotherapy. A review of pediatric cancer patients with nontransplant-associated SOS/VOD treated with defibrotide revealed 83 patients, and 66 were in remission. This review supports early treatment with defibrotide in patients with nontransplant-associated SOS/VOD. Topics: Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Polydeoxyribonucleotides | 2022 |
1 trial(s) available for defibrotide and Kidney-Neoplasms
Article | Year |
---|---|
Veno-occlusive disease in pediatric patients affected by Wilms tumor.
Hepatic veno-occlusive disease (VOD) is a rare and potentially severe complication of chemotherapy. We describe five patients who developed VOD after chemotherapy for Wilms tumor (WT) and evaluate the role of plasminogen activator inhibitor-1 (PAI-1) and defibrotide for diagnosis and therapy of VOD, respectively.. Thirty-five patients treated from 2002 to 2009 for WT were eligible. Diagnosis of VOD was according McDonald's criteria that required two of the following: jaundice, hepatomegaly and/or right upper quadrant pain, weight gain with or without ascites.. VOD occurred in 5 of 35 patients (14%) after 21-105 days from starting chemotherapy. Two patients developed multiorgan failure (MOF). PAI-1 was high in four patients who were tested. Three patients were treated with defibrotide and no side effects were reported while two patients received supportive measures only. Four patients recovered and three of them received defibrotide. They are all alive and well after a median follow-up of 35 months. One of two patients not treated with defibrotide died of MOF.. PAI-1 levels were abnormal in WT-VOD. Defibrotide was a safe, well-tolerated, and potentially efficacious therapy in this group of patients. Further prospective study is needed in WT-VOD to confirm these data. Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Female; Fibrinolytic Agents; Hepatic Veno-Occlusive Disease; Humans; Infant; Kidney Neoplasms; Male; Plasminogen Activator Inhibitor 1; Polydeoxyribonucleotides; Wilms Tumor | 2011 |
1 other study(ies) available for defibrotide and Kidney-Neoplasms
Article | Year |
---|---|
Education and imaging. Hepatobiliary and pancreatic: sinusoidal obstruction syndrome during chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Child, Preschool; Female; Hepatic Veno-Occlusive Disease; Humans; Kidney Neoplasms; Liver Function Tests; Neoadjuvant Therapy; Polydeoxyribonucleotides; Treatment Outcome; Ultrasonography, Doppler, Color; Wilms Tumor | 2011 |